

Appl. No. : 09/933,580

Filed : August 20, 2001

CLAIMS

1-12. (Cancelled)

13. (Currently Amended) A method of identifying a target protein in a biochemical pathway of a pathogen for pharmaceutical intervention comprising:

(a) selecting a first potential target protein in said biochemical pathway and expressed by a pathogen genome;

(b) retrieving a first interaction fingerprint comprising a set of values representative of binding strength between said potential target protein expressed by said pathogen genome and a corresponding set of ligands;

(c) retrieving a ~~different~~ second interaction fingerprint comprising a set of values representative of binding strength between a ~~different~~ protein expressed by the human genome and said set of ligands;

(d) ~~comparing~~ detecting differences between said first interaction fingerprint ~~with~~ and said second interaction fingerprint;

(e) repeating steps (c) and (d) for a plurality of different proteins encoded by a ~~selected genome~~ the human genome; and

(f) identifying said potential target protein as a target protein for pharmaceutical intervention based at least in part on said ~~repeated comparisons~~ detected differences.

14-19. (Cancelled)

20. (New) A method of assessing toxicity of a proposed pharmaceutical intervention, wherein one or more selected drug candidate molecules bind to a protein target for pharmaceutical intervention, said method of assessing comprising:

(a) selecting the protein target of said one or more drug candidate molecules, said protein target being expressed by a selected genome;

(b) retrieving a first interaction fingerprint comprising a set of values representative of binding strength between said protein target and a corresponding set of ligands;

(c) retrieving a second interaction fingerprint comprising a set of values representative of binding strength between a different protein expressed by the same genome and said set of ligands;

Appl. No. : 09/933,580

Filed : August 20, 2001

(d) detecting similarities between said first interaction fingerprint and said second interaction fingerprint;

(e) repeating steps (c) and (d) for a plurality of different proteins; and

(f) identifying said proposed pharmaceutical intervention as likely to exhibit toxicity based at least in part on said detected similarities.

Appl. No. : 09/933,580

Filed : August 20, 2001

SUMMARY OF INTERVIEW

The applicant thanks the Examiner for the interview of February 22, 2005. The enablement rejection was discussed. Possible amendments to the Claim 13 were also discussed with reference to clarifying the nature of the proteins being compared and the nature of the fingerprint comparison performed.